Stay updated with breaking news from Alkermes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com assumed coverage on shares of Alkermes (NASDAQ:ALKS – Free Report) in a research report report published on Tuesday morning. The brokerage issued a strong-buy rating on the stock. A number of other equities analysts have also recently issued reports on the company. Piper Sandler dropped their target price on Alkermes from $37.00 to $35.00 […]
Alkermes (NASDAQ:ALKS – Free Report) had its price objective boosted by Bank of America from $27.00 to $29.00 in a research note issued to investors on Tuesday, Benzinga reports. Bank of America currently has a neutral rating on the stock. A number of other research firms have also recently weighed in on ALKS. StockNews.com raised […]
A study demonstrated olanzapine and samidorphan’s (LYBALVI) safety, tolerability, and durability during a 4-yeat treatment period.
The data assess the extended efficacy of the treatment for up to 4 years.
Alkermes plc (ALKS) reported topline results from a phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI in patients with schizophrenia, schizophreniform disorder or bipolar I disorder for up to four years of treatment, following treatment received in prior LYBALVI studies.